Treatment Modalities for Idiopathic Macular Telangiectasia: An Evidence-Based Systematic Review of the Literature

REFERENCES

• Wu L, Evans T, Arevalo JF. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). Surv Ophthalmol 2013;58:536–59.
   PubMed Web of Science ®Google Scholar
• Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis: Update of classification and follow-up study. Ophthalmology 1993;100:1536–46.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Bardal AM, Freund KB, et al. Idiopathic macular telangiectasia. Arch Ophthalmol 2006;124:450–60.
   PubMedGoogle Scholar
• Eliassi-Rad B, Green WR. Histopathologic study of presumed parafoveal telangiectasis. Retina 1999;19:332–5.
   PubMed Web of Science ®Google Scholar
• Watzke RC, Klein ML, Folk JC, et al. Long-term juxtafoveal retinal telangiectasia. Retina 2005;25:727–35.
   PubMed Web of Science ®Google Scholar
• OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine 2011. http://www.cebm.net/index.aspx?o=5653 ( accessed October 31, 2014).
   Google Scholar
• Stoffelns BM, Schoepfer K, Kramann C. Idiopathic macular telangiectasia: Follow-up with and without laser photocoagulation. Klin Monbl Augenheilkd 2010;227:252–6.
   PubMed Web of Science ®Google Scholar
• Li KK, Goh TY, Parsons H, et al. Use of intravitreal triamcinolone acetonide injection in unilateral idiopathic juxtafoveal telangiectasis. Clin Experiment Ophthalmol 2005;33:542–4.
   PubMed Web of Science ®Google Scholar
• Shibeeb O, Vaze A, Gillies M, Gray T. Macular oedema in idiopathic macular telangiectasia type 1 responsive to aflibercept but not bevacizumab. Case Rep Ophthalmol Med 2014;2014:219792.
   PubMedGoogle Scholar
• Ciarnella A, Verrilli S, Fenicia V, et al. Intravitreal ranibizumab and laser photocoagulation in the management of idiopathic juxtafoveolar retinal telangiectasia type 1: A case report. Case Rep Ophthalmol 2012;3:298–303.
   PubMedGoogle Scholar
• Kotoula MG, Chatzoulis DZ, Karabatsas CH, et al. Resolution of macular edema in idiopathic juxtafoveal telangiectasis using PDT. Ophthalmic Surg Lasers Imaging 2009;40:65–7.
   PubMedGoogle Scholar
• Haller JA, Bandello F, R Belfort Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–1146.
   PubMed Web of Science ®Google Scholar
• OO Maia Jr, Takahashi WY, Bonanomi MT, et al. Intravitreal triamcinolone injection in the treatment of idiopathic juxtafoveal telangiectasis. Arq Bras Oftalmol 2006;69:941–4.
   PubMedGoogle Scholar
• Nema N, Ip MS. Intravitreal triamcinolone for management of idiopathic juxtafoveolar telangiectasis. Oman J Ophthalmol 2010;3:38–40.
   PubMedGoogle Scholar
• Loutfi M, Papathomas T, Kamal A. Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex). Case Rep Ophthalmol Med 2014;2014:231913.
   PubMedGoogle Scholar
• Sandali O, Akesbi J, Rodallec T, et al. Dexamethasone implant for the treatment of edema related to idiopathic macular telangiectasia. Can J Ophthalmol 2013;48:78–80.
   Web of Science ®Google Scholar
• Dunn EN, Gregori NZ, Goldhardt R. Phakic cystoid macular edema secondary to idiopathic macular telangiectasia type 1 responsive to topical anti-inflammatory agents. Semin Ophthalmol 2013;28:84–7.
   PubMed Web of Science ®Google Scholar
• Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111–8.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Chong V, Loewenstein A, et al. European Society of Retina Specialists: Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014;98:1144–67.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep 2014;14:510.
   PubMed Web of Science ®Google Scholar
• Schlingemann RO, Witmer AN. Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 2009;175:253–67.
   PubMed Web of Science ®Google Scholar
• García-Ben A, Gómez-Ulla F, Rodriguez-Cid MJ. Intravitreal bevacizumab in the treatment of idiopathic juxtafoveal telangiectasis type I. Arch Soc Esp Oftalmol 2014;89:269–71.
   PubMedGoogle Scholar
• De Bats F, Denis P, Kodjikian L. Idiopathic macular telangiectasia: Clinical appearance, imaging and treatment. J Fr Ophtalmol 2013;36:164–71.
   PubMed Web of Science ®Google Scholar
• Rouvas A, Malamos P, Douvali M, et al. Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia. Clin Ophthalmol 2013;7:1357–62.
   PubMedGoogle Scholar
• Moon BG, Kim YJ, Yoon YH, et al. Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2012;250:1697–9.
   PubMed Web of Science ®Google Scholar
• Koay CL, Chew FL, Visvaraja S. Bevacizumab and type 1 idiopathic macular telangiectasia. Eye 2011;25:1663–5.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Yuzawa M. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 2010;54:320–4.
   PubMed Web of Science ®Google Scholar
• Gamulescu MA, Walter A, Sachs H, et al. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2008;246:1189–93.
   PubMed Web of Science ®Google Scholar
• Moon SJ, Berger AS, Tolentino MJ, et al. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmic Surg Lasers Imaging 2007;38:164–6.
   PubMedGoogle Scholar
• Takayama K, Ooto S, Tamura H, et al. Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia. Eye 2010;24:1492–7.
   PubMed Web of Science ®Google Scholar
• Hutton WL, Snyder WB, Fuller D, et al. Focal parafoveal retinal telangiectasis. Arch Ophthalmol 1978;96:1362–7.
   PubMedGoogle Scholar
• Chopdar A. Retinal telangiectasis in adults: Fluorescein angiographic findings and treatment by argon laser. Br J Ophthalmol 1978;62:243–50.
   PubMed Web of Science ®Google Scholar
• Friedman SM, Mames RN, Stewart MW. Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafoveolar retinal telangiectasis. Ophthalmic Surg 1993;24:551–3.
   PubMedGoogle Scholar
• Lee BL. Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis. Retina 1996;16:344–6.
   PubMed Web of Science ®Google Scholar
• Lombardo J. Idiopathic juxtafoveolar retinal telangiectasis: Case report and literature review. Optometry 2002;73:103–12.
   PubMedGoogle Scholar
• Ferrer Novella E, Torrón Fernández-Blanco C, Ruiz Moreno O, et al. Exudative idiopathic juxtafoveolar retinal telangiectasis. Arch Soc Esp Oftalmol 2001;76:7–11.
   PubMedGoogle Scholar
• Lee SW, Kim SM, Kim YT, et al. Clinical features of idiopathic juxtafoveal telangiectasis in Koreans. Korean J Ophthalmol 2011;25:225–30.
   PubMedGoogle Scholar
• Meyer-ter-Vehn T, Herzog S, Schargus M, et al. Long-term course in type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2013;251:2513–20.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Ravalico G. Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2007;245:612–5.
   PubMed Web of Science ®Google Scholar
• Windisch R, Kozousek V. Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis. Can J Ophthalmol 2008;43:489–90.
   PubMed Web of Science ®Google Scholar
• Park DW, Schatz H, McDonald HR, et al. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997;104:1838–46.
   PubMed Web of Science ®Google Scholar
• Kiraly A, Nasemann JE. Idiopathic juxtafoveolar telangiectasis: Long-term follow-up of visual acuity. Ophthalmologe 1995;92:698–703.
   PubMedGoogle Scholar
• Hirano Y, Yasukawa T, Usui Y, et al. Indocyanine green angiography-guided laser photocoagulation combined with sub-Tenon’s capsule injection of triamcinolone acetonide for idiopathic macular telangiectasia. Br J Ophthalmol 2010;94:600–5.
   PubMed Web of Science ®Google Scholar
• RD Steigerwalt Jr, Pascarella A, Arrico L, et al. Idiopathic juxtafoveal retinal telangiectasis and retinal macroaneurysm treated with indocyanine green dye-enhanced photocoagulation. Panminerva Med 2012;54:93–6.
   PubMed Web of Science ®Google Scholar
• De Lahitte GD, Cohen SY, Gaudric A. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol 2004;138:892–4.
   PubMed Web of Science ®Google Scholar
• Potter MJ, Szabo SM, Chan EY, et al. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 2002;133:149–51.
   PubMed Web of Science ®Google Scholar
• Hershberger VS, Hutchins RK, Laber PW. Photodynamic therapy with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis. Ophthalmic Surg Lasers Imaging 2003;34:318–20.
   PubMedGoogle Scholar
• Snyers B, Verougstraete C, Postelmans L, et al. Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 2004;137:812–9.
   PubMed Web of Science ®Google Scholar
• Hussain N, Das T, Sumasri K, et al. Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis. Am J Ophthalmol 2005;140:333–5.
   PubMed Web of Science ®Google Scholar
• Potter MJ, Szabo SM, Sarraf D, et al. Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis. Can J Ophthalmol 2006;41:34–7.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Ravalico G. Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2007;245:612–5.
   PubMed Web of Science ®Google Scholar
• Dave V, Chhablani J, Narayanan R. Different treatment modalities for choroidal neovascularization in two eyes of one patient with bilateral type 2A parafoveal telangiectasia. Indian J Ophthalmol 2013;61:353–5.
   PubMed Web of Science ®Google Scholar
• Hussain N, Das T, Khanna R, et al. One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia. Clin Ophthalmol 2007;1:483–8.
   PubMedGoogle Scholar
• Shanmugam MP, Agarwal M. RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol 2005;53:61–3.
   PubMedGoogle Scholar
• Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113–6.
   PubMed Web of Science ®Google Scholar
• Martinez JA. Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 2003;121:1658–9.
   PubMedGoogle Scholar
• Cakir M, Kapran Z, Basar D, et al. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Eur J Ophthalmol 2006;16:711–7.
   PubMed Web of Science ®Google Scholar
• Maguluri S, Recchia CC, Recchia FM. Neurosensory macular detachment in group 2a juxtafoveolar telangiectasis and resolution following intravitreal triamcinolone. Retin Cases Brief Rep 2007;1:20–1.
   PubMedGoogle Scholar
• Wu L, Evans T, Arévalo JF, et al. Long-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasia. Retina 2008;28:314–9.
   PubMed Web of Science ®Google Scholar
• Eandi CM, Ober MD, Freund KB, et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: A pilot study. Retina 2006;26:780–5.
   PubMed Web of Science ®Google Scholar
• Do DV, Bressler SB, Cassard SD, et al. Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularisation. Retina 2014;34:2063–71.
   PubMed Web of Science ®Google Scholar
• Veloso CE, Vianna RN, Pelayes DE, et al. Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia. Ophthalmic Res 2013;49:205–8.
   PubMed Web of Science ®Google Scholar
• Meyer-ter-Vehn T, Herzog S, Schargus M, et al. Long-term course in type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2013;251:2513–20.
   PubMed Web of Science ®Google Scholar
• Toy BC, Koo E, Cukras C, et al. Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: Results of a phase II clinical trial. Retina 2012;32:996–1006.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Finger RP, Kruse K, et al. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: A 12-month prospective study. Am J Ophthalmol 2011;151:876–886.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Libondi T, von Baltz S, et al. Intravitreal bevacizumab for perifoveal telangiectasia. Acta Ophthalmol 2011;89:607–8.
   Web of Science ®Google Scholar
• Roller AB, Folk JC, Patel NM, et al. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 2011;31:1848–55.
   PubMed Web of Science ®Google Scholar
• Kovach JL, Rosenfeld PJ. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009;29:27–32.
   PubMed Web of Science ®Google Scholar
• Vianna RN, Squeri G, Turquetti R, et al. Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis. Can J Ophthalmol 2008;43:492–3.
   PubMed Web of Science ®Google Scholar
• Schulze S, Mennel S. Treatment of idiopathic juxtafoveolar retinal telangiectasis with bevacizumab (avastin). Klin Monbl Augenheilkd 2007;224:787–90.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Scholl HP, Holz FG. Short-term effects of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Retin Cases Brief Rep 2007;1:79–81.
   PubMedGoogle Scholar
• Sigler EJ, Randolph JC, Calzada JI, et al. Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2013;251:1097–101.
   PubMed Web of Science ®Google Scholar
• Matt G, Sacu S, Ahlers C, et al. Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2. Eye 2010;24:1535–41.
   PubMed Web of Science ®Google Scholar
• Lira RP, Silva VB, Cavalcanti TM, et al. Intravitreous ranibizumab as treatment for macular telangiectasia type 2. Arch Ophthalmol 2010;128:1075–8.
   PubMedGoogle Scholar
• Charbel Issa P, Finger RP, Holz FG, et al. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2008;92:941–5.
   PubMed Web of Science ®Google Scholar
• Windisch R, Kozousek V. Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis. Can J Ophthalmol 2008;43:489–90.
   PubMed Web of Science ®Google Scholar
• Dave V, Chhablani J, Narayanan R. Different treatment modalities for choroidal neovascularization in two eyes of one patient with bilateral type 2A parafoveal telangiectasia. Indian J Ophthalmol 2013;61:353–5.
   PubMed Web of Science ®Google Scholar
• Ozkaya A, Alkin Z, Karakucuk Y, et al. Long-term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2. Middle East Afr J Ophthalmol 2013;20:360–2.
   PubMedGoogle Scholar
• Narayanan R, Chhablani J, Sinha M, et al. Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina 2012;32:2001–5.
   PubMed Web of Science ®Google Scholar
• Mavrakanas N, Mendrinos E, Pournaras CJ, et al. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A. Acta Ophthalmol 2009;87:930–2.
   PubMed Web of Science ®Google Scholar
• Konstantinidis L, Mantel I, Zografos L, et al. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2009;247:1567–9.
   PubMed Web of Science ®Google Scholar
• Karagiannis D, Georgalas I, Ladas I, et al. A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis. Clin Interv Aging 2009;4:63–5.
   PubMed Web of Science ®Google Scholar
• Cakir M, Bayraktar Z, Bayraktar S, et al. Intravitreal bevacizumab treatment of retinal telangiectasis complicated by subretinal neovascularization. Retin Cases Brief Rep 2008;2:141–4.
   PubMedGoogle Scholar
• Shanmugam MP, Mythri HM, Shetty NS. Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane. Indian J Ophthalmol 2007;55:490–1.
   PubMedGoogle Scholar
• Ruys J, De Laey JJ, Vanderhaeghen Y, et al. Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. Eye 2007;21:1433–4.
   PubMed Web of Science ®Google Scholar
• OO Maia Jr, Bonanomi MT, Takahashi WY, et al. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am J Ophthalmol 2007;144:296–9.
   PubMed Web of Science ®Google Scholar
• Mandal S, Venkatesh P, Abbas Z, et al. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2007;245:1825–9.
   PubMed Web of Science ®Google Scholar
• Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 2007;245:1045–8.
   PubMed Web of Science ®Google Scholar
• Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004;138:884–5.
   PubMed Web of Science ®Google Scholar
• Rishi P, Rishi E, Shroff D. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia. Indian J Ophthalmol 2009;57:241–2.
   PubMed Web of Science ®Google Scholar
• Rishi P, Shroff D, Rishi E. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2008;246:619–21.
   PubMed Web of Science ®Google Scholar
• Zehetner C, Haas G, Treiblmayr B, et al. Reduced-fluence photodynamic therapy combined with ranibizumab for nonproliferative macular telangiectasia type 2. Ophthalmologica 2013;229:195–202.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Sanchez JG, Garcia RA, et al. Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: A pilot study. Graefes Arch Clin Exp Ophthalmol 2007;245:1673–80.
   PubMed Web of Science ®Google Scholar
• Shukla D, Singh J, Kolluru CM, et al. Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. Am J Ophthalmol 2004;138:147–9.
   PubMed Web of Science ®Google Scholar
• Nachiappan K, Shanmugam MP. Treatment of CNVM secondary to idiopathic juxtafoveal retinal telangiectasis by transpupillary thermotherapy. Am J Ophthalmol 2005;139:577–8.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Sohn EH, Folk JC, et al. Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors. Retina 2014;34:1400–6.
   PubMed Web of Science ®Google Scholar
• Berger AS, McCuen BW, Brown GC, et al. Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina 1997;17:94–98.
   PubMed Web of Science ®Google Scholar
• Terauchi G, Matsumoto CS, Shinoda K, et al. Pars plana vitrectomy combined with focal endolaser photocoagulation for idiopathic macular telangiectasia. Case Rep Med 2014;2014:786578.
   PubMedGoogle Scholar
• Charbel Issa P, Gillies MC, Chew EY, et al. Macular telangiectasia type 2. Prog Retin Eye Res 2013;34:49–77.
   PubMed Web of Science ®Google Scholar
• LaVail MM, Unoki K, Yasumura D, et al. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci U S A 1992;89:11249–53.
   PubMed Web of Science ®Google Scholar
• Wen R, Tao W, Li Y, et al. CNTF and retina. Prog Retin Eye Res 2012;31:136–51.
   PubMed Web of Science ®Google Scholar
• Hua J, Guerin KI, Chen J, et al. Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice. Invest Ophthalmol Vis Sci 2011;52:2809–16.
   PubMed Web of Science ®Google Scholar